| Literature DB >> 31877910 |
Nahid Norouzi-Gheidari1,2, Alejandro Hernandez3, Philippe S Archambault1,2, Johanne Higgins3,4, Lise Poissant3,4, Dahlia Kairy3,4.
Abstract
(1) Background: Increasing the amount of therapy time has been shown to improve motor function in stroke survivors. However, it is often not possible to increase the amount of therapy time provided in the current one-on-one therapy models. Rehabilitation-based virtual reality exergame systems, such as Jintronix, can be offered to stroke survivors as an adjunct to traditional therapy. The goal of this study was to examine the safety and feasibility of providing additional therapy using an exergame system and assess its preliminary clinical efficacy. (2)Entities:
Keywords: Kinect; exergames; rehabilitation; stroke; upper extremity; video games; virtual reality
Mesh:
Year: 2019 PMID: 31877910 PMCID: PMC6981843 DOI: 10.3390/ijerph17010113
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1The Jintronix rehabilitation exergaming system.
Characteristics of the stroke participants.
| Intervention Group ( | Control Group ( | |
|---|---|---|
|
| 5:4 | 5:4 |
|
| 42.2 ± 9.5 (22.7–52.6) | 57.6 ± 10.5 (41.7–73.6) |
|
| 5.7 ± 3.2 (2.6–12.9) | 8.4 ± 7.8 (2.0–23.3) |
|
| 9:0:0 | 8:0:1 |
|
| 4:5 | 3:6 |
|
| 7:2 | 8:1 |
|
| ||
|
| 4.2 ± 1.3 (3–6) | 4.0 ± 1.1 (3–6) |
|
| ||
|
| 25.6 ± 9.1 (12–36) | 26.9 ± 5.6 (21–36) |
|
| 5.3 ± 4.3 (0–10) | 6.8 ± 3.2 (0–10) |
|
| 9.4 ± 5.6 (1–14) | 10.3 ± 3.4 (3–14) |
|
| 3.9 ± 1.3 (2–6) | 4.0 ± 1.7 (2–6) |
|
| 44.2 ± 18.8 (15–63) | 48.0 ± 11.4 (28–62) |
|
| 27.0 ± 23.5 (0–54) | 33.1 ± 14.3 (2–48) |
|
| 1.9 ± 1.4 (0.0–4.1) | 2.0 ± 1.3 (0.5–4.9) |
|
| 2.9 ± 0.7 (2.0–4.0) | 3.4 ± 0.8 (2.3–4.9) |
|
| 63.3 ± 17.2 (34.0–82.7) | 68.7 ± 14.4 (44.1–87.1) |
|
| 68.2 ± 14.5 (40.4–82.7) | 71.3 ± 10.8 (54.6–88.7) |
The numbers beside ‘±’ sign represent mean ± standard deviation. The numbers in parentheses represent range. (/x) indicates maximum of the scale. * Difference in the baseline between the two groups is significant (p < 0.05).
Summary of the feasibility and safety outcome measures.
| ID | # of Sessions | Total Session Duration (min) | Total Exergaming Duration (min) | Session Efficiency (%) | Pain Level (VAS) | Fatigue (Borg Scale) | # of Falls | # of Dizziness | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | Std | Mean | Std | Mean | Std | Mean | Std | Mean | Std | ||||
|
| 8 | 50 | 6.0 | 26 | 5.3 | 53% | 12% | 0.0 | 0.0 | 0.6 | 0.9 | 0 | 0 |
|
| 8 | 47 | 3.7 | 23 | 3.7 | 50% | 10% | 0.4 | 0.7 | 3.4 | 0.7 | 0 | 0 |
|
| 8 | 41 | 3.2 | 16 | 2.9 | 40% | 8% | 0.0 | 0.0 | 1.6 | 1.4 | 0 | 0 |
|
| 9 | 42 | 2.6 | 13 | 3.0 | 31% | 7% | 0.8 | 1.7 | 0.3 | 1.0 | 0 | 0 |
|
| 11 | 42 | 5.1 | 22 | 4.1 | 54% | 9% | 0.0 | 0.0 | 2.9 | 1.7 | 0 | 0 |
|
| 8 | 44 | 3.2 | 18 | 2.8 | 41% | 6% | 0.4 | 0.5 | 1.2 | 0.5 | 0 | 0 |
|
| 8 | 42 | 4.2 | 24 | 4.9 | 56% | 7% | 1.4 | 0.9 | 1.3 | 0.7 | 0 | 1 |
|
| 9 | 48 | 5.8 | 29 | 5.0 | 62% | 5% | 0.0 | 0.0 | 1.8 | 1.0 | 0 | 0 |
|
| 8 | 43 | 4.5 | 26 | 3.1 | 63% | 4% | 1.1 | 1.4 | 1.5 | 0.5 | 0 | 0 |
|
| 8 | 44 | 3.2 | 17 | 3.5 | 39% | 5% | 2.1 | 1.0 | 2.0 | 0.0 | 0 | 0 |
|
|
|
|
|
|
|
|
|
|
|
| |||
* This participant is excluded from the subsequent analyses as the follow-up evaluations were not completed.
Values of the efficacy outcome measures over time.
| Outcome Measures | Baseline (T0) † | Post-Intervention (T1) ‡ | 4-Week Follow-Up (T2) ‡ | Change from T0 to T1 @ | Change from T0 to T2 @ |
|---|---|---|---|---|---|
|
| |||||
|
| 44.2 ± 18.8 | 46.3 ± 16.8 | 47.2 ± 14.7 | 2.1 | 3.0 |
|
| 1.9 ± 1.4 | 2.1 ± 1.7 | 2.3 ± 1.7 | 0.2 | 0.4 |
|
| 2.9 ± 0.7 | 3.6 ± 0.7 * | 3.4 ± 0.8 | 0.7 * | 0.5 |
|
| 27.0 ± 23.5 | 27.2 ± 22.8 | 29.4 ± 24.6 | 0.2 | 2.4 |
|
| 52.1 ± 15.0 | 56.3 ± 16.8 | 57.6 ± 18.4 | 4.2 | 5.6 |
|
| 85.2 ± 14.7 | 91.0 ± 10.4 * | 91.7 ± 10.3 * | 5.9 | 6.5 |
|
| 41.7 ± 33.6 | 52.2 ± 38.6 | 51.1 ± 34.9 | 10.6 | 9.4 |
|
| 74.4 ± 16.4 | 80.0 ± 14.8 | 78.4 ± 12.7 | 5.6 | 4.8 |
|
| 63.3 ± 17.2 | 69.9 ± 18.3 * | 69.2 ± 17.1 * | 6.5 * | 5.9 |
|
| 93.3 ± 6.8 | 97.2 ± 3.9 | 97.6 ± 5.1 | 4.0 | 4.4 |
|
| 67.0 ± 15.7 | 75.3 ± 22.2 | 81.5 ± 15.2 | 8.3 | 14.5 |
|
| 90.1 ± 14.3 | 92.5 ± 14.1 | 94.0 ± 9.4 | 2.4 | 4.0 |
|
| 54.2 ± 27.3 | 67.4 ± 24.8 | 61.1 ± 23.4 | 13.2 | 6.9 |
|
| 55.6 ± 23.1 | 65.6 ± 20.1 | 70.0 ± 22.1 | 10.0 | 14.4 |
|
| 68.2 ± 14.5 | 75.3 ± 14.9 | 75.8 ± 14.0 | 7.1 * | 7.6 * |
|
| |||||
|
| 48.0 ± 11.4 | 47.8 ± 12.3 | 47.6 ± 13.3 | −0.2 | −0.4 |
|
| 2.0 ± 1.3 | 2.1 ± 1.0 * | 1.9 ± 0.9 | 0.0 | −0.1 |
|
| 3.4 ± 0.8 | 2.9 ± 0.7 * | 3.5 ± 0.8 | −0.5 | 0.1 |
|
| 33.1 ± 14.3 | 31.6 ± 14.7 | 33.1 ± 12.5 | −1.6 | 0.0 |
|
| 59.7 ± 19.8 | 51.4 ± 14.9 | 59.0 ± 22.1 | −8.3 | −0.7 |
|
| 82.7 ± 14.2 | 85.2 ± 10.1 * | 83.3 ± 14.0 * | 2.5 | 0.6 |
|
| 53.9 ± 28.6 | 55.0 ± 25.1 | 61.1 ± 32.8 | 1.1 | 7.2 |
|
| 78.6 ± 16.0 | 75.6 ± 14.3 | 73.9 ± 19.9 | −3.1 | −4.7 |
|
| 68.7 ± 14.4 | 66.8 ± 13.4 * | 69.3 ± 18.3 * | −2.0 | 0.6 |
|
| 83.7 ± 14.4 | 82.1 ± 21.1 | 86.1 ± 19.4 | −1.6 | 2.4 |
|
| 69.1 ± 13.2 | 80.2 ± 9.9 | 78.7 ± 14.2 | 11.1 | 9.6 |
|
| 87.7 ± 13.7 | 88.9 ± 12.6 | 83.3 ± 21.2 | 1.2 | −4.4 |
|
| 60.1 ± 17.1 | 64.6 ± 23.9 | 63.9 ± 17.9 | 4.5 | 3.8 |
|
| 66.1 ± 15.4 | 70.6 ± 14.9 | 71.7 ± 18.2 | 4.4 | 5.6 |
|
| 71.3 ± 10.8 | 72.6 ± 11.1 | 73.5 ± 14.7 | 1.3 | 2.2 |
Abbreviations: FMA-UE, Fugl-Meyer Assessment-Upper Extremity; MAL, Motor Activity Log; AOU, Amount of Use; QOM, Quality of Movement; BBT, Box and Block Test; SIS, Stroke Impact Scale. † p-values noted in this column are for simple comparisons between the intervention and control groups. ‡ p-values noted in these columns are for between-group comparisons using Linear Mixed Model approach and setting baseline as a covariate. @ p-values noted in these columns are for testing changes between baseline and the specified time point in each group. * p < 0.05. The numbers beside ‘±’ represent mean ± standard deviation.
Figure 2Average and individual change scores of the efficacy outcome measures at pre, post, and follow-up evaluations.